We are driven to make a difference for patients and those who care for them.
At the heart of everything we do at Syros is our dedication to advancing medicines that provide a profound benefit for patients with difficult-to-treat diseases.
We are pioneering a new field of medicine focused on controlling the expression of genes. The genes expressed - turned on, off, up or down - in any given cell determine its type and function. When genes are expressed at the wrong time or in the wrong amounts, it changes the function of a cell, leading to disease. Because gene expression is fundamental to the function of all cells, we believe our pioneering approach has potential to create medicines that provide patients with a range of diseases the opportunity to live longer and enjoy a better quality of life.
We are currently advancing one program in a Phase 2 clinical trial and a second toward a Phase 1 clinical trial: SY-1425 in a defined subset of patients with acute myeloid leukemia; and SY-5609 in patients with select solid tumors, including breast, lung and ovarian cancers. In addition, we have multiple programs in earlier stages of research for cancer, as well as genetic diseases, for which there is a dire need for better medicines.
We invite you to learn more about our programs and our ongoing clinical trial, as well as to explore a select list of resources for these diseases.
Nancy Simonian, M.D.
Chief Executive Officer of Syros